BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21196716)

  • 1. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
    Nzouakou R; Bachir D; Lavaud A; Habibi A; Lee K; Lionnet F; Hulin A; Jouault H; Préhu C; Roudot-Thoraval F; Girot R; Galactéros F
    Acta Haematol; 2011; 125(3):145-52. PubMed ID: 21196716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
    Chaine B; Neonato MG; Girot R; Aractingi S
    Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A; Jerrell JM; Stallworth JR
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
    Ritho J; Liu H; Hartzema AG; Lottenberg R
    Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hydroxyurea treatment in patients affected with sickle cell anemia: efficacy and safety].
    de Montalembert M
    Transfus Clin Biol; 2008; 15(1-2):34-8. PubMed ID: 18499496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydroxyurea treatment of sickle cell anemia in hospital-based practices.
    Ferguson RP; Arun A; Carter C; Walker SD; Castro O
    Am J Hematol; 2002 Aug; 70(4):326-8. PubMed ID: 12214583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles.
    Lukusa AK; Vermylen C; Vanabelle B; Curaba M; Brichard B; Chantrain C; Dupont S; Ferrant A; Wyns C
    Pediatr Hematol Oncol; 2009 Jun; 26(4):186-94. PubMed ID: 19437321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of clinical response by hydroxyurea in 132 patients with major sickle cell anemia].
    Elira Dokekias A; Okandze Elenga JP; Ndinga J; Sanogo I; Sangare A
    Tunis Med; 2005 Jan; 83(1):32-7. PubMed ID: 15881719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
    de Montalembert M; Brousse V; Elie C; Bernaudin F; Shi J; Landais P;
    Haematologica; 2006 Jan; 91(1):125-8. PubMed ID: 16434381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
    Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
    Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K; Smith-Whitley K
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
    Fitzhugh CD; Wigfall DR; Ware RE
    Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.
    Puffer E; Schatz J; Roberts CW
    Child Neuropsychol; 2007 Mar; 13(2):142-54. PubMed ID: 17364571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Terrin ML; Moore RD; Dover GJ; Barton FB; Eckert SV; McMahon RP; Bonds DR
    N Engl J Med; 1995 May; 332(20):1317-22. PubMed ID: 7715639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.